Additional Charges Against Valeant Pharma (VRX) or Former Execs Cannot Be Ruled Out - Wells Fargo's Maris

November 17, 2016 1:46 PM EST
Get Alerts VRX Hot Sheet
Price: $15.46 +0.13%

Rating Summary:
    11 Buy, 11 Hold, 4 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade VRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Wells Fargo analyst David Maris weighed in on Valeant Pharma (NYSE: VRX) after today's DOJ press conference. Maris said based on the comments additional charges against Valeant or former Valeant executives cannot be ruled out,

Maris commented, "Earlier in the day, a Valeant spokesperson indicated that given the charges brought today involved fraud against Valeant and in their view it is difficult to be a victim and guilty at the same time, that today's news was somehow good news for Valeant, or at least not as bad as it could have been. Given Mr. Bharara's statement, we believe it is premature for investors to believe that charges against the company and/or former executives are not in their future. On the contrary, we believe based on today's statements by Mr. Bharara, additional charges against Valeant or former Valeant executives cannot be ruled out, given this well-resourced and ongoing investigation."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Litigation, Rumors, Trader Talk

Related Entities

Wells Fargo, David Maris

Add Your Comment